Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3525 - Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): final data analysis from South Australia


09 Oct 2016


Poster display


Adeola Ayoola


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


A. Ayoola1, S. Sukumaran2, R. Kumar1, D. Gordon3, A. Roy4, S. Vantandoust1, B. Koczwara2, G. Kichenadasse2, C. Karapetis4

Author affiliations

  • 1 Department Of Medical Oncology, Flinders Medical Center, 5042 - Bedford Park/AU
  • 2 Medical Oncology, Flinders Medical Centre and Flinders University, 5042 - Adelaide/AU
  • 3 Department Of Microbiology And Infectious Diseases, Flinders Medical Center, 5042 - Bedford Park/AU
  • 4 Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide/AU


Abstract 3525


Influenza (flu) virus infection has a significant morbidity and mortality in excess of 5-10% especially in patients with medical co-morbidities who are also immune-suppressed. Influenza vaccination decreases all-cause mortality by about 30-50%. Patients undergoing chemotherapy along with the general public are vaccinated annually; there has been no study to assess the efficacy of influenza vaccination in these groups (patients on chemotherapy- POCT).


This is a prospective single arm, phase II open label study. 53 POCT with non-haematological cancers were recruited between 2011 and 2012 influenza seasons. POCT vaccinated in the current influenza season were excluded. Participants had one dose of 2011/2012 trivalent FluVax containing strains A/California/7/2009(H1N1); A/Perth/16/2009 (H3N2); B/Brisbane/60/2008 at least 3 days before chemotherapy. Primary endpoint was early seroconversion (SC) rate at 3weeks; other end-points were late SC rate at 6weeks; sustained SC and sero-protection (SP) at 24 weeks. Haem-agglutination inhibition (HAI) titres in serum were measured at baseline, 3, 6 and 24 weeks. Endpoint defined as SP (HAI ≥ 40); SC (≥4-fold increase titre).


53 patients; mean (sd) age 58.3(10.5) years; n(%) of Females 31(58.5). The results are displayed in the table below.

Proportion N (%)
Baseline 3weeks 6weeks 6months
A/California/7/2009 (H1N1) 0 14 (35%) 14 (31.8%) 3 (7.5%)
A/Perth/16/2009(H3N2) 0 12 (30%) 12 (27.3%) 7 (17.5%)
B/Brisbane/60/2008 0 9 (22.5%) 8 (18.2%) 3 (7.5%)
A/California/7/2009 (H1N1) 23 (47.9%) 30 (75%) 33(75%) 16 (40%)
A/Perth/16/2009(H3N2) 19 (39.58%) 26 (65%) 26 (59.1%) 21 (52.5%)
B/Brisbane/60/2008 17 (42.5%) 17 (42.5%) 14 (31.8%) 8 (20%)


POCT might have sub-optimal response to the FluVax. Our findings should be confirmed in a larger patient population and warrants further research into a more effective strategy in this patient group.

Clinical trial identification


Legal entity responsible for the study

Southern Adelaide Health Network Inc




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings